       Document 0263
 DOCN  M9460263
 TI    Delayed-type hypersensitivity skin tests are an independent predictor of
       human immunodeficiency virus disease progression. Department of Veterans
       Affairs Cooperative Study Group.
 DT    9404
 AU    Gordin FM; Hartigan PM; Klimas NG; Zolla-Pazner SB; Simberkoff MS;
       Hamilton JD; Division of Infectious Diseases, VA Medical Center,
       Washington,; DC 20422.
 SO    J Infect Dis. 1994 Apr;169(4):893-7. Unique Identifier : AIDSLINE
       MED/94179907
 AB    Delayed-type hypersensitivity (DTH) testing was evaluated as a predictor
       of human immunodeficiency virus (HIV) disease progression in 336
       symptomatic patients with baseline CD4 cell counts of 200-500/mm3 who
       were participating in a randomized trial of early versus late therapy
       with zidovudine. Patients with a response of > 2 mm to any of seven
       antigens were categorized as reactive; those without were anergic.
       Anergic patients were significantly more likely than reactive patients
       to have HIV disease progression as evidenced by decrease in CD4 cell
       count (52% vs. 27%), development of AIDS (33% vs. 17%), or death (18%
       vs. 9%) (P < or = .02), irrespective of time of zidovudine initiation.
       By multivariate analysis, DTH results were an independent predictor of
       HIV progression separate from CD4 cell count, p24 antigen positivity, or
       level of beta 2-microglobulin. DTH skin tests are an independent
       predictor of HIV disease progression and may be of value in the
       evaluation of a patient's immune status.
 DE    beta 2-Microglobulin/ANALYSIS  Acquired Immunodeficiency
       Syndrome/ETIOLOGY  Adult  Age Factors  Cohort Studies  Double-Blind
       Method  Female  Human  *Hypersensitivity, Delayed  HIV Infections/DRUG
       THERAPY/ETIOLOGY/*IMMUNOLOGY/MORTALITY  Leukocyte Count  Male  Prognosis
       Proportional Hazards Models  Risk Factors  Skin Tests  Support, U.S.
       Gov't, Non-P.H.S.  Survival Rate  Treatment Outcome  T4 Lymphocytes
       Zidovudine/THERAPEUTIC USE  CLINICAL TRIAL  JOURNAL ARTICLE  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

